Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
veltuzumab · 2 trials · 21 indications
safety will be assessed by monitoring lab results and adverse events, which will be assessed every 3 months for up to 2 years.
| Arm | Type | Description |
|---|---|---|
| veltuzumab | EXPERIMENTAL | veltuzumab is a humanized CD20 antibody administered subcutaneously in this study. |
| Name | Type | Description |
|---|---|---|
| veltuzumab | BIOLOGICAL | veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks. |
Inclusion Criteria: * Histologically confirmed diagnosis of CD20 positive chronic lymphocytic leukemia (CLL) * Either previously untreated or relapsed * Measurable disease (at least one lesion \> 1.5 cm for NHL, or ALC \> 5,000 for CLL) see full protocol for additional criteria Exclusion Criteria:...
Veltuzumab is an investigational monoclonal antibody being studied for the treatment of Non-Hodgkin's Lymphoma (NHL). It is a CD20-targeted therapy developed by Gilead Sciences, Inc. (GILD). As of the available data, veltuzumab is in Phase 1 clinical development and is not yet approved by regulatory authorities.
Veltuzumab targets the CD20 antigen, which is expressed on B-cells. By binding to CD20, the antibody is designed to direct an immune response against malignant B-cells in conditions like Non-Hodgkin's Lymphoma. This mechanism is being evaluated in early-phase clinical trials to assess its safety and potential efficacy.
Veltuzumab is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The drug is an investigational monoclonal antibody in Phase 1 clinical development for Non-Hodgkin's Lymphoma, and it has not yet received regulatory approval.
Veltuzumab is in Phase 1 clinical development. It is an investigational drug for Non-Hodgkin's Lymphoma and has not been approved by the FDA or other regulatory bodies. The available clinical data includes completed Phase 1 trials, and the drug remains under investigation for its safety and efficacy.
Veltuzumab has been studied in two completed Phase 1 clinical trials. NCT00546793 evaluated subcutaneous administration in patients with NHL and CLL, enrolling 32 participants in the United States. NCT00596804 assessed different doses in CD20+ Non-Hodgkin's Lymphoma, enrolling 39 participants in France and the United Kingdom.
Yes, veltuzumab is also known as hA20. In clinical trials, the drug is referred to by both names, such as in NCT00546793, which is titled 'Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL.' This alternative name is used interchangeably in research contexts.